BF-200 ALA + methyl-aminolevulinate
Phase 3Completed 1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Basal Cell Carcinoma (BCC)
Conditions
Basal Cell Carcinoma (BCC)
Trial Timeline
Jan 28, 2014 → Sep 9, 2020
NCT ID
NCT02144077About BF-200 ALA + methyl-aminolevulinate
BF-200 ALA + methyl-aminolevulinate is a phase 3 stage product being developed by Biofrontera for Basal Cell Carcinoma (BCC). The current trial status is completed. This product is registered under clinical trial identifier NCT02144077. Target conditions include Basal Cell Carcinoma (BCC).
What happened to similar drugs?
1 of 6 similar drugs in Basal Cell Carcinoma (BCC) were approved
Approved (1) Terminated (2) Active (3)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02144077 | Phase 3 | Completed |
Competing Products
20 competing products in Basal Cell Carcinoma (BCC)